Table 2.
Predictors of decline in LVEF and GLS following treatment with Trastuzumab
| ≥ 10% decline in LVEF | ≥ 15% decline in GLS | ||||||
|---|---|---|---|---|---|---|---|
| Yes | No | P-Value | Yes | No | P-Value | ||
| BMI Category | |||||||
| Normal | 1 (10%) | 9 (90%) | 0.76 | 2 (20%) | 8 (80%) | 0.53 | |
| Overweight | 3 (17.6%) | 14 (82.4%) | 1 (5.9%) | 16 (94.1%) | |||
| Obese | 2(22.2%) | 7 (77.8%) | 1 (11.1%) | 8 (88.9%) | |||
| Baseline heart rate, median (IQR) | 88.5 (26.75) | 90 (12.5) | 0.564 | 82.5 (27.75) | 90 (12.5) | 0.33 | |
| Baseline systolic blood pressure, median (IQR) | 135 (44.5) | 120 (15.75) | 0.04 | 115 (17.5) | 120 (19.75) | 0.19 | |
| Baseline diastolic blood pressure, median (IQR) | 85 (20.25) | 80 (12.75) | 0.22 | 82.5 (16.25) | 80 (14.25) | 0.38 | |
| Past medical history | |||||||
| Diabetes mellitus | 1 (25%) | 3 (75%) | 0.53 | 0 | 4 (100%) | 0.61 | |
| Hypertension | 3 (42.9%) | 4 (57.1%) | 0.07 | 1 (14.3%) | 6 (85.7%) | 0.59 | |
| Hyperlipidemia | 2 (25%) | 6 (75%) | 0.4 | 1 (12.5%) | 7 (87.5%) | 0.65 | |
| Coronary artery disease | 1 (50%) | 1 (50%) | 0.31 | 0 | 2 (100%) | 0.78 | |
| Cancer details | |||||||
| Laterality of breast cancer | |||||||
| Right breast | 3 (21.4%) | 11 (78.6) | 0.65 | 1 (7.1%) | 13 (92.9%) | 0.49 | |
| Left breast | 3 (13.6%) | 19 (86.4%) | 3 (13.6%) | 19 (86.4%) | |||
| Receptor status | |||||||
| ER-Positive | 3 (15.8%) | 16 (84.2%) | 0.61 | 1 (5.3%) | 18 (94.7%) | 0.32 | |
| PR-Positive | 4 (17.4%) | 19 (82.6%) | 0.63 | 1 (4.3%) | 22 (95.7%) | 0.12 | |
| Presence of metastasis | 1 (16.7%) | 5 (83.3%) | 0.74 | 0 | 6 (100%) | 0.46 | |
| Previous radiation therapy | 3 (10.7%) | 25 (89.3%) | 0.1 | 3 (10.7%) | 25 (89.3%) | 0.65 | |
LVEF: left ventricular ejection fraction, GLS: global longitudinal strain, BMI: body mass index, IQR: interquartile range, ER: estrogen receptor, PR: progesterone receptor